

Dr. Antoni Dávalos trained in neurology at the Vall d'Hebron University Hospital in Barcelona and qualified as a neurologist in 1984, obtaining his PhD degree in 1985. From 1986 to 2004 he developed his professional activity as Head of the Department of Neurology and Scientific Director at the Hospital Doctor Josep Trueta of Girona, Spain. From October 2004, he is the Director of the Department of Neurosciences at the Hospital Universitari Germans Trias i Pujol in Barcelona, Spain, Clinical Director of the Stroke Program at public hospitals (Institut Català de la Salut) in Catalonia and Professor of Medicine (Neurology) at the Autonomous University of Barcelona.

His clinical research has focused on cerebrovascular diseases particularly on the mechanisms associated with neurological deterioration, hemorrhagic transformation and brain edema in the acute phase of stroke, and in reperfusion therapies. He has published more than 440 original papers, book chapters or abstract proceedings on cerebrovascular diseases. Dr. Dávalos led or was on the steering committee in a number of drug trials such on thrombolytic therapy and neuroprotection.

His main recent achievements were on the field of the endovascular treatment of acute ischemic stroke. His team described for the first time the utility of stent retrievers for endovascular thrombectomy and he lead, in collaboration with Prof. Tudor Jovin from the Pittsburgh University Stroke Center, the REVASCAT study, a pivotal multicenter trial conducted by vascular neurologists and interventional neuroradiologists in four comprehensive stroke centers entirely located in Catalonia (Spain). REVASCAT demonstrated the efficacy and safety of endovascular thrombectomy with stent retrievers in patients with acute ischemic stroke and large vessel occlusions and that the benefit was sustained by 1 year (New Engl J Med 2015; Lancet Neurology 2017). Dr. Dávalos received an unrestricted grant from Medtronic, California, USA to conduct the study that was sponsored by the Fundació Ictus Malaltia Vascular (www.fundacioictus.com/?lang=es). The positive results of this Catalan collaboration, together with the positive results of four parallel trials in Netherlands, USA, Canada and Australia have changed the paradigm of acute ischemic stroke treatment all over the World and have updated the stroke guidelines for all the scientific societies as a treatment of Class I Level A.

Dr. Dávalos has been awarded by his research career by the American Neurological Association, the Catalanian College of Physicians, the Society for Vascular and Interventional Neurology (SVIN), the Spanish Neurological Society, the Institut Català de la Salut and the Pfizer Foundation in Spain.